Oncolytics Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ONCY and other ETFs, options, and stocks.

About ONCY

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. 

CEO
Jared Kelly
CEOJared Kelly
Employees
28
Employees28
Headquarters
Calgary, Alberta
HeadquartersCalgary, Alberta
Founded
1998
Founded1998
Employees
28
Employees28

ONCY Key Statistics

Market cap
115.68M
Market cap115.68M
Price-Earnings ratio
-3.77
Price-Earnings ratio-3.77
Dividend yield
Dividend yield
Average volume
1.36M
Average volume1.36M
High today
$1.09
High today$1.09
Low today
$1.01
Low today$1.01
Open price
$1.04
Open price$1.04
Volume
1.72M
Volume1.72M
52 Week high
$1.51
52 Week high$1.51
52 Week low
$0.3258
52 Week low$0.3258

Stock Snapshot

As of today, Oncolytics Biotech(ONCY) shares are valued at $1.06. The company's market cap stands at 115.68M, with a P/E ratio of -3.77.

During the trading session on 2026-03-09, Oncolytics Biotech(ONCY) shares reached a daily high of $1.09 and a low of $1.01. At a current price of $1.06, the stock is +5.0% higher than the low and still -2.8% under the high.

Trading activity shows a volume of 1.72M, compared to an average daily volume of 1.36M.

The stock's 52-week range extends from a low of $0.33 to a high of $1.51.

The stock's 52-week range extends from a low of $0.33 to a high of $1.51.

ONCY News

Simply Wall St 36m
Is Oncolytics Biotech Pricing Reflect The Gap To Its DCF Estimated Value

If you are wondering whether Oncolytics Biotech's current share price reflects its true worth, you are not alone, many investors are asking the same question be...

Is Oncolytics Biotech Pricing Reflect The Gap To Its DCF Estimated Value
TipRanks 5d
Oncolytics Biotech Advances Pelareorep Into New Phase 2 Colorectal Cancer Study

Oncolytics Biotech (ONCY) announced an update on their ongoing clinical study. The Phase 2 study “An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLF...

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

People also own

Based on the portfolios of people who own ONCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.